Mefruside


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Oedema 25-50 mg/day, up to 75-100 mg/day if needed. For long-term therapy: 25-50 mg every 2nd or 3rd day. HTN 25-50 mg/day alone or w/ other antihypertensives, alternate-day maintenance dosage may be used.
Dosage Details
Oral
Oedema
Adult: 25-50 mg daily, increase if necessary to 75-100 mg. For long-term therapy: 25-50 mg every 2nd or 3rd day.

Oral
Hypertension
Adult: 25-50 mg daily alone or in combination with other antihypertensives, alternate-day maintenance dosage may be used.
Contraindications
Severe hepatic or renal impairment; anuria; Addison's disease; hypercalcaemia.
Special Precautions
Fluid and electrolyte disturbances; hepatic cirrhosis; gout. Elderly; severe heart failure; renal impairment. Monitor blood glucose concentrations in patients taking antidiabetics. Lupus erythematosus. Pregnancy and lactation.
Adverse Reactions
Electrolyte imbalance; hyperglycaemia; gout; dry mouth; thirst; weakness; muscle pain and cramp; seizures; hypotension; GI disturbances; anorexia; sialadenitis; headache; impotence; yellow vision; hypersensitivity reactions; cholestatic jaundice; pancreatitis; blood dyscrasias; dizziness; photosensitivity reactions, postural hypotension, paraesthesia.
Drug Interactions
Increased toxicity of digitalis glycosides, allopurinol, tetracyclines. Increased risk of arrhythmia with drugs that prolong the QT interval. Hypotension with other antihypertensives, alcohol, barbiturates, opioids. Increased effects of neuromuscular blockers. Diuretic effects may be antagonised by NSAIDs, corticosteroids, carbenoxolone.
Potentially Fatal: Increased lithium toxicity.
Action
Description: Mefruside reduces the reabsorption of electrolytes from the renal tubules, hence increasing the excretion of sodium and chloride ions and, therefore, of water. It also reduces the glomerular filtration rate.
Onset: 2-4 hrs.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Mefruside from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in